Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.

@article{Artac2017PrognosticIO,
  title={Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.},
  author={Mehmet Artac and M{\"u}kremin Uysal and Mustafa Karaağaç and Levent Korkmaz and Zehra Er and Tunç G{\"u}ler and Melih Cem B{\"o}r{\"u}ban and Hakan Şat Bozcuk},
  journal={Journal of gastrointestinal cancer},
  year={2017},
  volume={48 2},
  pages={176-180}
}
PURPOSE Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil-leucovorin-irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach. Hence, there is a strong need for identifying new prognostic factors to show the efficacy of FOLFIRI-bev. METHODS This is a retrospective study including patients (n = 90) with mCRC from two centers in Turkey. Neutrophil/lymphocyte (N/L) ratio, platelet count, albumin, and C-reactive protein (CRP) were recorded before FOLFIRI-bev… CONTINUE READING